HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $405 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $405.
September 18, 2023 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $405.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Alnylam Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100